Sonrotoclax in Mantle Cell Lymphoma: ASH 2025 Clinical Takeaways

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
On location at ASH 2024 in Orlando, join Dr. Agrima Mian, Hematology/Oncology Fellow at the Cleveland Clinic and Chair of the ASH Trainee Council, for an insightful conversation with Dr. Sam Yamshon, Lymphoma Specialist, Assistant Professor, and Director of Cellular Therapies at NYU.
They dive into the most exciting and practice-changing data presented at the meeting, with a focus on novel therapies for B-cell lymphomas.
Key Discussion Points:
• Mantle Cell Lymphoma (MCL): Analyzing the promising new BCL2 inhibitor, sonrotoclax—its single-agent efficacy in heavily pre-treated patients, favorable toxicity profile (low TLS risk), and potential future in combination frontline regimens (like BOVen, MAVO) for high-risk disease.
• The Rise of Bispecific Antibodies: Why bispecifics are becoming the "biggest player" in lymphoma. Highlights include:
1. The groundbreaking EPCORE NHL-2 data with epcoritamab + R² (Revlimid & Rituximab) in follicular lymphoma, showing remarkable efficacy (HR 0.3).
2. Their expanding role in frontline DLBCL for unfit/frail patients, potentially challenging R-mini-CHOP.
3. Critical unanswered questions: de-escalating combinations (is lenalidomide always needed?) and defining optimal time-limited therapy.
• Community Oncology Translation: Will bispecific antibodies see wider uptake? Dr. Yamshon discusses the learning curve, parallels to the adoption of ADCs and rituximab, and how approvals in solid tumors (like tarlatamab for SCLC) are accelerating comfort and access in community practices.
A must-watch for hematologists, oncologists, fellows, and anyone interested in the rapidly evolving landscape of lymphoma treatment.

#ASH2024 #ASH24 #Lymphoma #MantleCellLymphoma #MCL #BCL2inhibitor #Sonrotoclax #BispecificAntibodies #Epcoritamab #DLBCL #FollicularLymphoma
Categoria
Oncology
Commenta per primo questo video.

Prossimo